⚕️ Medical Disclaimer
⚕️ Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any peptide.
Why Blood Work Is Non-Negotiable Before Peptides
Here is a fact that stops most biohackers mid-scroll: MK-677 (ibutamoren) raised IGF-1 levels by 40-60% in elderly subjects over 12 months — but it also elevated fasting glucose, highlighting why baseline HbA1c testing is absolutely essential before use (Svensson et al., 1998, PMID: 10404019). That single study captures the entire argument for pre-peptide blood work in a nutshell. Every compound you introduce into your body acts on specific biochemical pathways, and those pathways have measurable baseline values that can — and should — be recorded before you change anything.
Last updated: March 2026
Whether you are starting a GLP-1 agonist for weight management, a GH secretagogue for recovery, or BPC-157 for gut healing, a pre-protocol blood panel is your insurance policy. It gives you a reference point to measure progress, catch early warning signs, and prove to yourself (and your clinician) that what you are doing is either working or needs adjustment.
Think of it this way: you would not start a road trip without checking your fuel gauge, oil level, and tire pressure. Blood work is the pre-flight checklist for your metabolic engine. Skip it, and you are flying blind.
What Blood Panels Should I Order Before Starting Peptide Therapy?
Order a comprehensive baseline panel that covers metabolic, hormonal, inflammatory, and organ-function markers — the specific panels depend on which peptide class you plan to use. Here is the complete matrix:
| Panel Name | Key Markers | Relevant Peptide Classes | Normal Reference Range | Retest Interval |
|---|---|---|---|---|
| Comprehensive Metabolic Panel (CMP) | Glucose, BUN, creatinine, ALT, AST, ALP, electrolytes | All peptides | Glucose: 70-100 mg/dL; ALT/AST: 7-56 U/L | Baseline, 6 wk, 12 wk |
| Complete Blood Count (CBC) | WBC, RBC, hemoglobin, hematocrit, platelets | GH secretagogues, thymosin peptides | Hgb: 12-17.5 g/dL; WBC: 4,500-11,000 | Baseline, 12 wk |
| HbA1c | Glycated hemoglobin (90-day glucose average) | MK-677, GLP-1 agonists, tesamorelin | 4.0-5.6% (normal); 5.7-6.4% (prediabetic) | Baseline, 12 wk |
| Fasting Insulin | Serum insulin | GLP-1s, MK-677, GH secretagogues | 2.6-24.9 µIU/mL | Baseline, 12 wk |
| IGF-1 | Insulin-like growth factor 1 | All GH secretagogues, MK-677, tesamorelin | Age-dependent: 115-307 ng/mL (adults) | Baseline, 6 wk, 12 wk |
| Lipid Panel | Total cholesterol, LDL, HDL, triglycerides | GLP-1s, tesofensine, AOD-9604 | LDL: <100 mg/dL; Trigs: <150 mg/dL | Baseline, 12 wk |
| Thyroid Panel (TSH, Free T4, Free T3) | Thyroid function | GH secretagogues, tesamorelin | TSH: 0.4-4.0 mIU/L | Baseline, 12 wk |
| Liver Function (hepatic panel) | ALT, AST, GGT, bilirubin, albumin | All peptides (especially oral) | ALT/AST: 7-56 U/L | Baseline, 6 wk, 12 wk |
| Inflammatory Markers (CRP, ESR) | C-reactive protein, sed rate | BPC-157, TB-500, thymosin alpha-1 | CRP: <3.0 mg/L; ESR: 0-22 mm/hr | Baseline, 8 wk |
| Kidney Function (eGFR) | Estimated glomerular filtration rate | All peptides | >60 mL/min/1.73m² | Baseline, 12 wk |
For GH secretagogues like MK-677 and ipamorelin, IGF-1 and fasting glucose are non-negotiable. For GLP-1 agonists, add HbA1c and a lipid panel. For recovery peptides like TB-500 and BPC-157, inflammatory markers are helpful but not critical.
A baseline panel typically runs $150-400 out of pocket through direct-access labs like Quest, LabCorp, or online services.
Interpreting IGF-1 Results Following GH Secretagogue Initiation
IGF-1 is the primary biomarker for GH secretagogue efficacy — your goal is to reach the upper third of your age-adjusted reference range, not to exceed it. IGF-1 is produced by the liver in response to growth hormone and has a half-life of about 12-15 hours, making it a more stable indicator of average GH exposure than GH itself (which pulses unpredictably).
Here is a simplified interpretation framework:
• Below age-adjusted midpoint: Your GH secretagogue dose may be too low, your timing may be off (injecting in a fed state blunts GH release), or you may benefit from a different compound.
• Upper third of reference range (say 250-350 ng/mL for a 30-40-year-old): This is the sweet spot. Maximum anti-aging and recovery benefit with low risk.
• Above reference range (>400+ ng/mL): Reduce your dose. Chronically elevated IGF-1 is associated with increased cancer risk in epidemiological studies.
Important nuance: AOD-9604 is a fragment of the hGH molecule designed to stimulate fat loss without raising IGF-1 or affecting overall GH signaling. Studies on AOD-9604 showed it acts through beta-3 adrenergic mechanisms rather than the classical GH/IGF-1 axis (Heffernan et al., 2001, PMID: 11713213). This means if you are using AOD-9604, you do not need a GH panel — focus on metabolic markers instead.
Clinical Retesting Schedule During Peptide Cycling
Retest at 6 weeks for fast-acting markers (glucose, IGF-1) and at 12 weeks for slow-moving markers (HbA1c, lipids) — with an immediate retest if you experience any red-flag symptoms. Here is the protocol:
Baseline (Week 0 — before first dose): Complete panel. This is your reference point for everything that follows. Fast for 10-12 hours before the draw. Draw blood in the morning between 7-10 AM for consistent results across retests.
Week 6 midpoint check: Retest fasting glucose, IGF-1 (if using GH secretagogues), CMP, and any markers that were borderline at baseline. This is your first opportunity to catch emerging problems like glucose elevation from MK-677 or liver enzyme bumps.
Week 12 comprehensive retest: Full panel repeat. Compare everything against baseline. HbA1c needs 90 days to reflect average glucose, so this is your first valid HbA1c checkpoint. Lipid panels also need 8-12 weeks to show meaningful changes from GLP-1 therapy.
Post-cycle (4 weeks after last dose): Verify that all markers have returned to baseline. This is especially important for GH secretagogues — you want to confirm IGF-1 has normalized.
Peptide-Specific Lab Markers Categorization
Different peptide classes affect different systems. Here is your cheat sheet for which markers matter most by category:
GLP-1 Receptor Agonists (semaglutide, tirzepatide, retatrutide): HbA1c and fasting glucose are your primary endpoints. These drugs are designed to lower blood sugar and improve insulin sensitivity. A lipid panel (particularly triglycerides) is your secondary outcome — GLP-1s typically lower trigs by 15-25%. Liver enzymes (ALT/AST) should be monitored.
GH Secretagogues (ipamorelin, CJC-1295, GHRP-2, MK-677, tesamorelin): IGF-1 is the headline number. Fasting glucose and fasting insulin are critical because GH antagonizes insulin — meaning GH secretagogues can push you toward insulin resistance if you are predisposed.
Recovery Peptides (BPC-157, TB-500, thymosin alpha-1): For these, a baseline CBC and inflammatory markers (CRP, ESR) provide the best context. BPC-157 is gastroprotective and should not significantly alter standard blood markers.
Fat-Loss Compounds (AOD-9604, 5-Amino-1MQ, tesofensine): Focus on metabolic markers: fasting glucose, HbA1c, lipid panel, and liver enzymes.
Nootropic Peptides (selank, semax, pinealon, dihexa): Standard blood panels are less informative here because these compounds act primarily on the CNS. A baseline thyroid panel is worthwhile.
Clinical Red Flags Requiring Protocol Cessation
Stop your protocol immediately and contact your healthcare provider if any of the following appear in your blood work.
• Fasting glucose >125 mg/dL or HbA1c >6.4%: This is the diagnostic threshold for diabetes. Do not rationalize this away.
• IGF-1 significantly above reference range: Chronically supraphysiological IGF-1 (>1.5x upper limit) increases cancer risk.
• ALT or AST >3x upper limit of normal: This indicates potential liver injury. Pause all oral peptides and any hepatically-metabolized compounds.
• eGFR sudden drop >25%: Acute kidney function decline warrants immediate medical evaluation.
• Hematocrit >54% (men) or >48% (women): Elevated red blood cell mass increases thrombosis risk.
• Lipase or amylase >3x upper limit of normal with GI symptoms: Possible pancreatitis, particularly associated with GLP-1 agonists.
• Sudden, unexplained increase in inflammatory markers: A CRP spike from <1 to >10 during a recovery peptide protocol could indicate infection at an injection site.
Bottom line: blood work exists to protect you. No peptide goal is worth ignoring a clear warning signal.
Final Word
⚕️ Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any peptide.
Last updated: March 2026. Medical guidance evolves — verify with your clinician.